Stay updated on Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Revision: v3.4.2 replaces v3.4.1 as a minor metadata update with no changes to study content or results; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-13T11:51:40.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1 on the page.
    Difference
    0.0%
    Check dated 2026-02-05T23:45:34.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.3 to v3.3.4 on the page, a minor metadata change that does not affect study information or usability.
    Difference
    0.0%
    Check dated 2026-01-15T04:16:45.000Z thumbnail image
  5. Check
    62 days ago
    Change Detected
    Summary
    The page now includes a single Locations section listing California, Minnesota, New Jersey, New York, Texas, and Washington, consolidating the study sites under one heading and removing the previous state-specific location entries.
    Difference
    0.7%
    Check dated 2025-12-24T12:21:09.000Z thumbnail image
  6. Check
    91 days ago
    Change Detected
    Summary
    A note explains that PubMed publications shown are auto-filled and may not pertain to the study. Revision: v3.3.2 is now listed.
    Difference
    0.1%
    Check dated 2025-11-25T13:51:21.000Z thumbnail image
  7. Check
    99 days ago
    Change Detected
    Summary
    The funding-status notice about potential data updates due to government funding lapses is removed, along with the associated operating-status guidance. The page no longer displays the disclaimer and the link to opm.gov for updates.
    Difference
    0.3%
    Check dated 2025-11-18T07:21:26.000Z thumbnail image

Stay in the know with updates to Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.